In the clinic, the treatment strategy for breast cancer is determined by the presence or absence of three receptors: the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor (HER2). This evidence concerns the gene ERBB2 and breast carcinoma.